Lucid Diagnostics（LUCD）株式概要
ルシッド・ダイアグノスティックス社は、米国で商業段階の医療診断技術会社として事業を展開している。 詳細
LUCD Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
IN
Community Contributor
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.
View narrativeUS$5
FV
80.0% 割安 内在価値ディスカウント79
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Lucid Diagnostics Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.00 |
| 52週高値 | US$1.70 |
| 52週安値 | US$0.90 |
| ベータ | 1.1 |
| 1ヶ月の変化 | -23.08% |
| 3ヶ月変化 | -27.54% |
| 1年変化 | -24.81% |
| 3年間の変化 | -35.06% |
| 5年間の変化 | n/a |
| IPOからの変化 | -91.50% |
最新ニュース
ナラティブの更新 • Apr 25
LUCD: Higher Future P/E Assumptions Will Support Upside Despite Execution Risks
Analysts have lifted their price target on Lucid Diagnostics by $0.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple as the key drivers of the change. Analyst Commentary While the higher price target reflects updated modeling assumptions, bearish analysts still flag several areas of concern that readers should keep in mind when thinking about Lucid Diagnostics.
ナラティブの更新 • Apr 11
LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing
Analysts have adjusted their price target on Lucid Diagnostics from $8.25 to $9.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations. Analyst Commentary Recent research highlights a constructive tone around Lucid Diagnostics, with bullish analysts pointing to updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations as key reasons behind the higher price target of US$9.00.Recent updates
ナラティブの更新 • Apr 25
LUCD: Higher Future P/E Assumptions Will Support Upside Despite Execution Risks
Analysts have lifted their price target on Lucid Diagnostics by $0.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple as the key drivers of the change. Analyst Commentary While the higher price target reflects updated modeling assumptions, bearish analysts still flag several areas of concern that readers should keep in mind when thinking about Lucid Diagnostics.ナラティブの更新 • Apr 11
LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing
Analysts have adjusted their price target on Lucid Diagnostics from $8.25 to $9.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations. Analyst Commentary Recent research highlights a constructive tone around Lucid Diagnostics, with bullish analysts pointing to updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations as key reasons behind the higher price target of US$9.00.
新しいナラティブ • Apr 01
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.ナラティブの更新 • Mar 27
LUCD: VA Contract Will Drive Broader Future Adoption And Repricing
Analysts have raised their price target for Lucid Diagnostics to $8.25. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and a very high anticipated future P/E multiple.ナラティブの更新 • Mar 12
LUCD: VA Contract Will Expand Screening Access And Support Future Upside
Analysts have modestly adjusted their price target for Lucid Diagnostics to reflect slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value estimate steady at $2.50. What's in the News Lucid Diagnostics received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, aimed at expanding access to esophageal precancer testing across the VA healthcare system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).ナラティブの更新 • Feb 26
LUCD: VA Screening Access And Safety Data Will Support Future Upside
Analysts kept their Lucid Diagnostics price target steady at $2.50, pointing to largely unchanged fair value and P/E assumptions, with only small tweaks to the discount rate, revenue growth, and profit margin inputs behind their models. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, making the test available across the VA's national integrated healthcare system that serves more than 9 million enrolled veterans each year (Key Developments).ナラティブの更新 • Feb 11
LUCD: VA Screening Contract And Real World Data Will Support Future Upside
Analysts have modestly revised their price target on Lucid Diagnostics, citing adjusted assumptions for the discount rate, revenue growth, profit margin, and future P/E that maintain a fair value estimate of $2.50. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, giving VA hospitals and facilities nationwide a single procurement framework and expanding access across the system that serves more than nine million enrolled veterans annually (Key Developments).ナラティブの更新 • Jan 27
LUCD: VA Contract And Real World Screening Data Will Support Future Upside
Analysts have adjusted their price target for Lucid Diagnostics slightly, maintaining fair value at about US$2.50 while fine tuning assumptions on the discount rate, revenue growth, profit margins and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News Lucid Diagnostics secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing across the VA system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Seeking Alpha • Jan 26
Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral
Summary Lucid offers an office-based esophageal precancer screening. The FDA cleared EsoCheck sampling plus EsoGuard NGS epigenetic assay to triage EGD referrals. In my view, their core upside hinges on broader Medicare coverage. The recent CAC support and 45-day notice suggest improving odds on this front. LUCD’s Q3 2025 showed 2,841 tests and $7.1 million in pro-forma revenues billed. But, only $1.2 million could be conservatively recognized. So, there’s still considerable friction for LUCD’s underlying business. Fortunately, real-world evidence looks promising, and the VA FSS contract is a green flag. I think LUCD is heading in the right direction. But it still sports a premium valuation despite its several uncertainties and dilution risks. So I remain neutral on the stock. Read the full article on Seeking Alphaナラティブの更新 • Jan 13
LUCD: Real World Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have slightly reduced their price target on Lucid Diagnostics, citing updated assumptions that keep fair value steady at $2.50 while reflecting small adjustments to the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News New real world data on Lucid Diagnostics EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device cover 11,991 at risk patients over 18 months of routine clinical use between January 2023 and June 2024 (medRxiv preprint).ナラティブの更新 • Dec 14
LUCD: New Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have raised their price target on Lucid Diagnostics by approximately 25 percent to reflect higher projected revenue growth, slightly improved long term profitability, and a modestly higher valuation multiple despite a small uptick in the assumed discount rate. What's in the News Reported new 18-month real-world data in 11,991 at-risk patients using EsoGuard and EsoCheck for nonendoscopic Barrett's esophagus screening, supporting their utility as scalable, noninvasive tools in routine clinical practice (company announcement) Study authors highlighted excellent safety and tolerability, with EsoCheck achieving a 95% technical success rate, most procedures completed in under two minutes, and no serious adverse events (company announcement) Most patients in the analysis met U.S. gastroenterology society guideline criteria for Barrett's esophagus screening, indicating appropriate physician adoption of EsoGuard and EsoCheck (company announcement) Valuation Changes Fair Value: risen moderately from 2.0x to 2.5x, reflecting a higher implied valuation multiple on forward fundamentals.分析記事 • Dec 13
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
新しいナラティブ • Apr 12
Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets
Expanding reimbursement coverage and leveraging NCCN guidelines are strategies expected to enhance revenue and credibility with payers.分析記事 • May 09
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Dec 15
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Aug 11
Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio
Lucid Diagnostics (NASDAQ:LUCD) announced on Thursday that its subsidiary, LucidDx Labs, has launched four new Lucid Test Centers in California, Texas, Florida and Ohio. Patients in the metropolitan areas with chronic heartburn can order from their own physician or from a telemedicine physician and can now undergo a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer, using Lucid’s EsoGuard DNA Esophageal Test. The test centers are staffed with Lucid-employed nurse practitioners who use EsoCheck to collect surface esophageal cells which are sent to LucidDx Labs for EsoGuard testing. (LUCD) has risen ~2% premarket.分析記事 • Jul 07
We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...株主還元
| LUCD | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -2.0% | 4.0% | -0.3% |
| 1Y | -24.8% | -18.6% | 26.7% |
業界別リターン: LUCD過去 1 年間で-18.6 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: LUCDは、過去 1 年間で26.7 % のリターンを上げたUS市場を下回りました。
価格変動
| LUCD volatility | |
|---|---|
| LUCD Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: LUCD 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: LUCDの 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2018 | 82 | Lishan Aklog | www.luciddx.com |
ルシッド・ダイアグノスティックス社は、米国で商業段階の医療診断技術会社として活動している。食道前癌や癌（主に致死性の高い食道腺癌）発症リスクのある胃食道逆流症（GERD）患者に焦点を当てている。同社の主力製品であるEsoGuard Esophageal DNA Testは、EsoCheck Esophageal Cell collection deviceで採取したサンプルを用いて実施する検査ツールであり、リスクのあるGERD患者の食道前がんを早期に発見することでEACによる死亡を予防することを目的としている。同社は2018年に法人化され、ニューヨーク州ニューヨークを拠点としている。Lucid Diagnostics Inc.はPAVmed Inc.の子会社として営業している。
Lucid Diagnostics Inc. 基礎のまとめ
| LUCD 基礎統計学 | |
|---|---|
| 時価総額 | US$180.66m |
| 収益（TTM） | -US$58.18m |
| 売上高(TTM) | US$5.13m |
37.2x
P/Sレシオ-3.3x
PER（株価収益率LUCD は割高か？
公正価値と評価分析を参照収益と収入
| LUCD 損益計算書（TTM） | |
|---|---|
| 収益 | US$5.13m |
| 売上原価 | US$6.74m |
| 売上総利益 | -US$1.61m |
| その他の費用 | US$56.57m |
| 収益 | -US$58.18m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.30 |
| グロス・マージン | -31.36% |
| 純利益率 | -1,133.21% |
| 有利子負債／自己資本比率 | 630.0% |
LUCD の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 07:04 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Lucid Diagnostics Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |